Findings With the Antibody Drug Conjugate D3-GPC2-PBD
April 18th 2018Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
Watch
The Significance of Brain Metastases in Non-Small Cell Lung Cancer
March 21st 2018Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer.
Watch
Earlier Pseudoprogression Seen in Patients With Oligodendroglioma Treated With Proton Therapy
March 21st 2018Patients with oligodendroglioma developed pseudoprogression earlier after treatment with proton therapy compared with after photon therapy, according to the results of a retrospective study comparing the rates of pseudoprogression that occurred in patients with anaplastic gliomas following treatment with different radiation therapy modalities.
Read More
TTFields with Temozolomide Recommended by NCCN for Newly Diagnosed GBM
March 21st 2018The combination of TTFields and temozolomide has been added by the NCCN to its guidelines for Category 1 treatment for patients with newly diagnosed glioblastoma, following maximal safe resection and completion of radiation therapy.
Read More
Cabozantinib Active in Relapsed/Refractory Glioblastoma
February 21st 2018In results of a phase II study, cabozantinib (Cabometyx) showed signs of activity in patients with progressive glioblastoma who were naïve to antiangiogenic therapy, despite the predefined statistical target for success not being met.
Read More